Back to News
Market Impact: 0.35
Ultragenyx To Sell Rare Pediatric Disease Voucher For $210 Mln
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
Ultragenyx Pharmaceutical entered into a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher for $210 million. The article does not specify when the sale will close or how the proceeds will be used.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
RARE0.55
More News
- Ultragenyx shares rise after agreeing to sell FDA priority review voucher for $210 million
- Former world No. 1 Jon Rahm's lawyer tells court Spaniard is done with LIV Golf after three seasons
- Anthropic will be 'most ridiculous IPO' of year, analyst says
- Levi Strauss hikes profit guidance after tariff refunds, but its sales outlook is less optimistic
- Samsung Q3 profit surges to record high, but misses lofty expectations
- Brazil is having its Argentina moment. How to play it